These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 3625198)

  • 21. Hormonal effects of apomorphine in schizophrenia.
    Ferrier IN; Johnstone EC; Crow TJ
    Br J Psychiatry; 1984 Apr; 144():349-57. PubMed ID: 6722395
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Growth hormone levels and lithium ratios as predictors of success of lithium therapy in schizophrenia.
    Hirschowitz J; Zemlan FP; Garver DL
    Am J Psychiatry; 1982 May; 139(5):646-9. PubMed ID: 6803597
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Apomorphine stimulation of vasopressin- and oxytocin-neurophysins. Evidence for increased oxytocinergic and decreased vasopressinergic function in schizophrenics.
    Legros JJ; Gazzotti C; Carvelli T; Franchimont P; Timsit-Berthier M; von Frenckell R; Ansseau M
    Psychoneuroendocrinology; 1992 Nov; 17(6):611-7. PubMed ID: 1287681
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Apomorphine and schizophrenia. Treatment, CSF, and neuroendocrine responses.
    Levy MI; Davis BM; Mohs RC; Kendler KS; Mathé AA; Trigos G; Horvath TB; Davis KL
    Arch Gen Psychiatry; 1984 May; 41(5):520-4. PubMed ID: 6372737
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Growth hormone response to apomorphine.
    Ferrier IN; Johnstone EC; Crow TJ
    Arch Gen Psychiatry; 1987 Jan; 44(1):93-4. PubMed ID: 3800586
    [No Abstract]   [Full Text] [Related]  

  • 26. Nocturnal growth hormone secretion in schizophrenic patients and healthy subjects.
    Kahn RS; Davidson M; Hirschowitz J; Stern RG; Davis BM; Gabriel S; Moore C; Davis KL
    Psychiatry Res; 1992 Feb; 41(2):155-61. PubMed ID: 1574542
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The blunted plasma cortisol response to apomorphine and its relationship to treatment response in patients with schizophrenia.
    Meltzer HY; Lee MA; Jayathilake K
    Neuropsychopharmacology; 2001 Mar; 24(3):278-90. PubMed ID: 11166518
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prolactin and growth hormone responses to growth hormone-releasing hormone in acute schizophrenia.
    Nerozzi D; Magnani A; Sforza V; Scaramucci E; Cerilli M; Moretti C; Antonozzi I; Frajese G
    Neuropsychobiology; 1990; 23(1):15-7. PubMed ID: 2280826
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neuroendocrine studies with dopamine agonists in schizophrenia.
    Rotrosen J; Angrist B; Paquin J
    Psychopharmacol Bull; 1978 Jan; 14(1):14-7. PubMed ID: 625529
    [No Abstract]   [Full Text] [Related]  

  • 30. Dopamine receptor alteration in schizophrenia: neuroendocrine evidence.
    Rotrosen J; Angrist BM; Gershon S; Sachar EJ; Halpern FS
    Psychopharmacology (Berl); 1976 Dec; 51(1):1-7. PubMed ID: 827770
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of amitriptyline treatment on the growth hormone response to apomorphine.
    Cowen PJ; Braddock LE; Gosden B
    Psychopharmacology (Berl); 1984; 83(4):378-9. PubMed ID: 6436869
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectof sex, oral contraceptives, and glucose loading on apomorphine-induced growth hormone secretion.
    Ettigi P; Lal S; Martin JB; Friesen HG
    J Clin Endocrinol Metab; 1975 Jun; 40(6):1094-8. PubMed ID: 1133158
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of apomorphine on blood levels of homovanillic acid, growth hormone and prolactin in medicated schizophrenics and healthy control subjects.
    Scheinin M; Syvälahti EK; Hietala J; Huupponen R; Pihlajamäki K; Seppälä OP; Säkö E
    Prog Neuropsychopharmacol Biol Psychiatry; 1985; 9(4):441-9. PubMed ID: 2866563
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Growth hormone response to clonidine in neuroleptic-free patients with multidagnostically defined schizophrenia.
    Keks NA; Copolov DL; McKenzie DP; Kulkarni J; Hassett A; Matheson B; Hill C; Mackie B; Singh B; Hirt J
    Psychiatry Res; 1993 Jul; 48(1):79-90. PubMed ID: 8416019
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum cholesterol levels in paranoid and non-paranoid schizophrenia associated with physical violence or suicide attempts in Taiwanese.
    Huang T; Wu S
    Psychiatry Res; 2000 Oct; 96(2):175-8. PubMed ID: 11063790
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clozapine effects on neuroendocrine response to apomorphine challenge testing in chronic neuroleptic nonresponsive schizophrenia: preliminary findings.
    Szymanski S; Lieberman J; Pollack S; Safferman A; Munne R; Umbricht D; Kane J; Kronig M; Chakos M; Cooper T
    Biol Psychiatry; 1995 Jan; 37(1):52-5. PubMed ID: 7893860
    [No Abstract]   [Full Text] [Related]  

  • 37. Behavioral and endocrine responses of schizophrenic patients to TRH (protirelin).
    Prange AJ; Loosen PT; Wilson IC; Meltzer HY; Fang VS
    Arch Gen Psychiatry; 1979 Sep; 36(10):1086-93. PubMed ID: 112944
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Elevated response of growth hormone to graded doses of apomorphine in schizophrenic patients.
    Müller-Spahn F; Modell S; Ackenheil M; Brachner A; Kurtz G
    J Psychiatr Res; 1998; 32(5):265-71. PubMed ID: 9789204
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Social disability in schizophrenia: the controlled prospective Burghölzli study II. Premorbid living situation and social adjustment--comparison with a normal control sample.
    Isele R; Merz J; Malzacher M; Angst J
    Eur Arch Psychiatry Neurol Sci; 1985; 234(5):348-56. PubMed ID: 3987744
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Amino acid patterns in schizophrenia: some new findings.
    Macciardi F; Lucca A; Catalano M; Marino C; Zanardi R; Smeraldi E
    Psychiatry Res; 1990 Apr; 32(1):63-70. PubMed ID: 2161549
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.